Loading
A phase 2 trial of toripalimab in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.
A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer is a phase 2, interventional study registered as NCT06878625 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 138 participants, started 2024-12-06 and due to reach its primary completion in 2027-06-30. Interventions recorded: Sacituzumab Govitecan combined with Toripalimab; Sacituzumab govitecan combined with anti-angiogenesis. Conditions listed: Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Histologically confirmed triple-negative invasive breast cancer, defined as immunohistochemical detection of ER \< 10%, PR \< 10%, HER2 0-1+ or HER2 2+ with negative FISH or CISH results, in accordance with the 2018 ASCO-CAP HER2-negative identification guidelines". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Toripalimab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/